Clinical Trial Results:
A Multi-Center, Randomized, Double-Blind, Parallel-Group Vehicle Controlled Study To Compare The Efficacy And Safety Of CD5789 50μg/g Cream Versus Vehicle Cream In Subjects With Acne Vulgaris
Summary
|
|
EudraCT number |
2016-002860-15 |
Trial protocol |
DE CZ |
Global end of trial date |
14 Nov 2017
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
06 Apr 2019
|
First version publication date |
06 Apr 2019
|
Other versions |
|
Summary report(s) |
Synopsis |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
RD.06.SPR.18251
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT02566369 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Galderma S.A.
|
||
Sponsor organisation address |
Avenue Gratta-Paille 2, Lausanne, Switzerland, 1018
|
||
Public contact |
CTA Coordinator, Galderma S.A., +41 21 642 78 00, cta.coordinator@galderma.com
|
||
Scientific contact |
CTA Coordinator, Galderma S.A., +41 21 642 78 00, cta.coordinator@galderma.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
Yes
|
||
EMA paediatric investigation plan number(s) |
EMEA-001492-PIP01-13 | ||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
Yes
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
17 Jan 2018
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
14 Nov 2017
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
14 Nov 2017
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
Multi-center, randomized, double blind, vehicle controlled study, to assess the efficacy and safety of CD5789 50 microgram/g cream in subjects 9 years of age and older with moderate acne vulgaris on face
and trunk, when applied once daily for 12 weeks.
|
||
Protection of trial subjects |
All subjects were required to read and sign an informed consent. The subjects could withdraw from the treatment at any time and for any reason.
|
||
Background therapy |
Not applicable | ||
Evidence for comparator |
Not applicable | ||
Actual start date of recruitment |
30 Nov 2015
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Germany: 124
|
||
Country: Number of subjects enrolled |
Hungary: 88
|
||
Country: Number of subjects enrolled |
United States: 802
|
||
Country: Number of subjects enrolled |
Canada: 139
|
||
Country: Number of subjects enrolled |
Puerto Rico: 55
|
||
Worldwide total number of subjects |
1208
|
||
EEA total number of subjects |
212
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
19
|
||
Adolescents (12-17 years) |
573
|
||
Adults (18-64 years) |
616
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
||||||||||||||||||||||||||||||||||
Recruitment
|
||||||||||||||||||||||||||||||||||
Recruitment details |
A total of 1208 subjects were enrolled and exposed to CD5789 50 microgram/g cream or vehicle cream for 12 weeks. A minimum of 14 days between Screening and Baseline visit (+/- 3 days). Study visits for Weeks 1,2,4,8 (+/- 3 days) and Week 12 (+/- 5 days). | |||||||||||||||||||||||||||||||||
Pre-assignment
|
||||||||||||||||||||||||||||||||||
Screening details |
Male or Female subjects, 9 years of age and older, with moderate acne vulgaris, with at least 20 inflammatory lesions and 25 non-inflammatory lesions for face, and , at least 20 inflammatory and 20- 100 non-inflammatory on the trunk. No more than 1 nodule on the face and trunk. Inclusion criteria for trunk was optional for subjects ages 9 to 11. | |||||||||||||||||||||||||||||||||
Period 1
|
||||||||||||||||||||||||||||||||||
Period 1 title |
Overall (overall period)
|
|||||||||||||||||||||||||||||||||
Is this the baseline period? |
Yes | |||||||||||||||||||||||||||||||||
Allocation method |
Randomised - controlled
|
|||||||||||||||||||||||||||||||||
Blinding used |
Double blind | |||||||||||||||||||||||||||||||||
Roles blinded |
Subject, Investigator | |||||||||||||||||||||||||||||||||
Arms
|
||||||||||||||||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
|||||||||||||||||||||||||||||||||
Arm title
|
CD5789 50 microgram/g cream | |||||||||||||||||||||||||||||||||
Arm description |
- | |||||||||||||||||||||||||||||||||
Arm type |
Experimental | |||||||||||||||||||||||||||||||||
Investigational medicinal product name |
CD5789 50 microgram/g cream
|
|||||||||||||||||||||||||||||||||
Investigational medicinal product code |
CD5789
|
|||||||||||||||||||||||||||||||||
Other name |
trifarotene
|
|||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Cream
|
|||||||||||||||||||||||||||||||||
Routes of administration |
Cutaneous use
|
|||||||||||||||||||||||||||||||||
Dosage and administration details |
A thin layer of study product cream (one pump actuation) was applied to the face region: forehead, nose, chin, area between the nose and upper lip, and each cheek. Avoid application proximity in/close to
eyes, angles of mouth, lips and mucous membranes.
A thin layer of study product cream (two pump actuations) was applied to the truncal region: right and left upper back, right and left shoulders and right and left anterior chest, self-reachable by the subject. Avoid application to axillary region, anterior and posterior neck.
Apply daily, in the evening, for 12 weeks, after washing the treated areas with preferred mild or soapless cleanser and allow to fully dry before applying study drug. The use of non comedogenic moisturizer was encouraged to be used as desired but respecting an interval of 1 hour (before and after) study drug application.
|
|||||||||||||||||||||||||||||||||
Arm title
|
Vehicle cream | |||||||||||||||||||||||||||||||||
Arm description |
- | |||||||||||||||||||||||||||||||||
Arm type |
Placebo | |||||||||||||||||||||||||||||||||
Investigational medicinal product name |
Vehicle cream
|
|||||||||||||||||||||||||||||||||
Investigational medicinal product code |
N/A
|
|||||||||||||||||||||||||||||||||
Other name |
placebo
|
|||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Cream
|
|||||||||||||||||||||||||||||||||
Routes of administration |
Cutaneous use
|
|||||||||||||||||||||||||||||||||
Dosage and administration details |
A thin layer of study product cream (one pump actuation) was applied to the face region: forehead, nose, chin, area between the nose and upper lip, and each cheek. Avoid application proximity in/close to
eyes, angles of mouth, lips and mucous membranes.
A thin layer of study product cream (two pump actuations) was applied to the truncal region: right and left upper back, right and left shoulders and right and left anterior chest, self-reachable by the subject. Avoid application to axillary region, anterior and posterior neck.
Apply daily, in the evening, for 12 weeks, after washing the treated areas with preferred mild or soapless cleanser and allow to fully dry before applying study drug. The use of non comedogenic moisturizer was encouraged to be used as desired but respecting an interval of 1 hour (before and after) study drug application.
|
|||||||||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
CD5789 50 microgram/g cream
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Vehicle cream
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
CD5789 50 microgram/g cream
|
||
Reporting group description |
- | ||
Reporting group title |
Vehicle cream
|
||
Reporting group description |
- |
|
|||||||||||||
End point title |
Absolute Change in Facial Inflammatory Lesion Count | ||||||||||||
End point description |
|||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
Baseline to Week 12
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Absolute Change in Inflammtory Lesion Count (Face) | ||||||||||||
Comparison groups |
CD5789 50 microgram/g cream v Vehicle cream
|
||||||||||||
Number of subjects included in analysis |
1208
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
< 0.001 | ||||||||||||
Method |
ANCOVA | ||||||||||||
Parameter type |
Least Square Mean Difference | ||||||||||||
Point estimate |
-3.6
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
-4.9 | ||||||||||||
upper limit |
-2.2 |
|
|||||||||||||
End point title |
Absolute Change in Facial Non Inflammatory Lesions | ||||||||||||
End point description |
|||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
Baseline to Week 12
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Absolute Change in Non-Inflammatory (Face) | ||||||||||||
Comparison groups |
CD5789 50 microgram/g cream v Vehicle cream
|
||||||||||||
Number of subjects included in analysis |
1208
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
< 0.001 | ||||||||||||
Method |
ANCOVA | ||||||||||||
Parameter type |
Least Square Mean Difference | ||||||||||||
Point estimate |
-7.1
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
-9.4 | ||||||||||||
upper limit |
-4.8 |
|
|||||||||||||
End point title |
IGA Success Rate (Face) | ||||||||||||
End point description |
|||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
Baseline to Week 12
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
IGA Success Rate | ||||||||||||
Comparison groups |
CD5789 50 microgram/g cream v Vehicle cream
|
||||||||||||
Number of subjects included in analysis |
1208
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
< 0.001 | ||||||||||||
Method |
Cochran-Mantel-Haenszel | ||||||||||||
Parameter type |
Risk difference (RD) | ||||||||||||
Point estimate |
9.8
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
4.8 | ||||||||||||
upper limit |
14.8 | ||||||||||||
Variability estimate |
Standard deviation
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
Baseline to Week 12
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse event reporting additional description |
Overall Summary of Treatment Emergent Adverse Events
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
18.0
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
CD5789 50 microgram/g cream
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Vehicle cream
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 1% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
20 Sep 2016 |
Increase in the number of study centers to 120 centers due to slow recruitment |
||
06 Mar 2017 |
1.Increased the number of study centers in order to meet study completion deadline:
a. 40 new sites in US, Canada and Puerto Rico
b. 18 new sites in Europe, Germany and Hungary
2.Extended recruitment duration to 23 months
|
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
Not applicable |